Neuroinflammation in Obesity, Alzheimer’s disease, and Depression.
Join the AAGP Journal Club and presenter Cyrus Raji MD, PhD at 3:15 pm Eastern Time on Friday. April 12, 2024. Dr. Raji will present on his publication in the AJGP from 10/2023 entitled “Neuroinflammation: A Modifiable Pathway Linking Obesity, Alzheimer’s Disease, and Depression”
ACCME Credit Designation Statement:
Update coming
Learning Objectives:
- Develop a working mechanistic knowledge of how chronic neuroinflammation from obesity and metabolic syndrome contributes to the pathophysiology of both depression and Alzheimer’s disease.
- Review past pharmacologic and non-pharmacologic interventions aimed at reducing neuroinflammation in obesity, depression, and Alzheimer’s disease, as well as ongoing neuroimaging initiatives utilized to measure neuroinflammation in living persons.
Continuing Education (CE) Language
American Association for Geriatric Psychiatry /AAGP
American Association for Geriatric Psychiatry Journal Club – Neuroinflammation in Obesity, Alzheimer’s disease, and Depression.
April 12, 2024
Online
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and American Association for Geriatric Psychiatry. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Amedco Joint Accreditation #4008163.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Objectives – After Attending This Program You Should Be Able To
1. Develop a working mechanistic knowledge of how chronic neuroinflammation from obesity and metabolic syndrome
contributes to the pathophysiology of both depression and Alzheimer’s disease.
2. Review past pharmacologic and non-pharmacologic interventions aimed at reducing neuroinflammation in obesity,
depression, and Alzheimer’s disease, as well as ongoing neuroimaging initiatives utilized to measure neuroinflammation.
in living persons
Disclosure of Conflict of Interest
The following table of disclosure information is provided to learners and contains the relevant financial relationships that
each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a
conflict of interest and have been resolved. (C7 SCS 6.1-6.2, 6.5)
All individuals in a position to control the content of CE are listed below.
